Jpmorgan Chase & CO Editas Medicine, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 924,806 shares of EDIT stock, worth $3.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
924,806
Previous 787,599 17.42%
Holding current value
$3.29 Million
Previous $1 Million 7.2%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$1.14 - $3.2 $156,415 - $439,062
137,207 Added 17.42%
924,806 $1.07 Million
Q4 2024

Feb 12, 2025
BUY
$1.2 - $3.76 $19,702 - $61,735
16,419 Added 2.13%
787,599 $1 Million
Q3 2024

Dec 26, 2024
SELL
$3.39 - $5.96 $94,981 - $166,987
-28,018 Reduced 3.51%
771,180 $2.63 Million
Q3 2024

Nov 08, 2024
SELL
$3.39 - $5.96 $94,981 - $166,987
-28,018 Reduced 3.51%
771,180 $2.63 Million
Q2 2024

Dec 26, 2024
BUY
$4.67 - $7.28 $130,844 - $203,971
28,018 Added 3.63%
799,198 $3.73 Million
Q2 2024

Aug 12, 2024
SELL
$4.67 - $7.28 $851,448 - $1.33 Million
-182,323 Reduced 18.58%
799,198 $3.73 Million
Q1 2024

Dec 26, 2024
BUY
$7.03 - $11.07 $1.48 Million - $2.33 Million
210,341 Added 27.28%
981,521 $7.28 Million
Q1 2024

May 10, 2024
SELL
$7.03 - $11.07 $488,486 - $769,210
-69,486 Reduced 6.61%
981,521 $7.28 Million
Q4 2023

Dec 26, 2024
BUY
$6.25 - $11.11 $1.75 Million - $3.11 Million
279,827 Added 36.29%
1,051,007 $10.6 Million
Q4 2023

Feb 12, 2024
SELL
$6.25 - $11.11 $58,025 - $103,145
-9,284 Reduced 0.88%
1,051,007 $10.6 Million
Q3 2023

Nov 14, 2023
SELL
$6.92 - $9.31 $444,360 - $597,832
-64,214 Reduced 5.71%
1,060,291 $8.27 Million
Q2 2023

Aug 11, 2023
SELL
$6.36 - $11.47 $53,716 - $96,875
-8,446 Reduced 0.75%
1,124,505 $9.25 Million
Q1 2023

May 18, 2023
BUY
$7.03 - $11.53 $608,798 - $998,498
86,600 Added 8.28%
1,132,951 $8.21 Million
Q1 2023

May 11, 2023
SELL
$7.03 - $11.53 $958,210 - $1.57 Million
-136,303 Reduced 11.53%
1,046,351 $7.59 Million
Q4 2022

Feb 13, 2023
BUY
$8.32 - $13.21 $160,808 - $255,322
19,328 Added 1.66%
1,182,654 $10.5 Million
Q3 2022

Nov 14, 2022
SELL
$12.16 - $19.42 $453,264 - $723,880
-37,275 Reduced 3.1%
1,163,326 $14.2 Million
Q2 2022

Aug 11, 2022
SELL
$9.99 - $21.35 $559,040 - $1.19 Million
-55,960 Reduced 4.45%
1,200,601 $14.2 Million
Q1 2022

May 11, 2022
SELL
$14.08 - $27.63 $2.92 Million - $5.73 Million
-207,502 Reduced 14.17%
1,256,561 $23.9 Million
Q4 2021

Feb 10, 2022
BUY
$26.55 - $40.57 $8.93 Million - $13.6 Million
336,305 Added 29.82%
1,464,063 $38.9 Million
Q3 2021

Nov 12, 2021
BUY
$39.27 - $72.94 $44.3 Million - $82.3 Million
1,127,758 New
1,127,758 $46.3 Million

Others Institutions Holding EDIT

# of Institutions
217
Shares Held
45.5M
Call Options Held
476K
Put Options Held
338K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $245M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email